Navacaprant
Navacaprant is a selective κ-opioid receptor antagonist which is under development for the treatment of major [depressive disorder] and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in Phases of [clinical research#Phase III|phase 3] clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.